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Canadian Health Measures SurveyPooling of surplus serum from individual samples, collected between 2007 and 2009 during Cycle 1 of the
CanadianHealthMeasures Survey (CHMS),was performed to develop a national baseline estimate of brominated
ﬂame retardants in Canadians. Serum sampleswere categorized by sex anddistributed byﬁve age groups ranging
from 6 to 79years. Nearly 5000 (4583) serum samples were used to form 59 composite pools. Serum pools were
created to ensure a high detection frequency of these analytes in serum because low volume samples had previ-
ously resulted in non-detectable concentrations. The analytes of interest in these serum pools included 23
polybrominated diphenyl ethers (PBDEs) and three hexabromocyclododecane (HBCD) isomers (α-, β- and
γ-HBCD). PBDEs were observed in all samples tested and total PBDE concentrations ranged from 27 ng g−1
lipid to 130ngg−1 lipid (geometric mean [GM] 46ngg−1 lipid).∑PBDE concentrations were signiﬁcantly ele-
vated in samples representing the 6–11year old age group (GM 65ngg−1 lipid) relative to ages above 40years,
although no difference in concentration was observed between the sexes. PBDE concentrations in Canadian sera
from the general populationwere higher than reported in Europe and Asia, but a little lower than observed in the
US. PBDE 47was the greatest contributor to∑PBDE concentrations and the GM concentration for this congener
was 22ngg−1 lipid. The other dominant contributors to∑PBDE concentrations were in descending order: 153
[GM9.4ngg−1 lipid]N99 [GM4.6ngg−1 lipid]≅100 [GM4.1ngg−1 lipid]N209 [GM1.1ngg−1 lipid] and 183 [GM
0.42ngg−1 lipid].∑HBCD was detected in all samples analysed, althoughmost samples were observed at con-
centrations b1ngg−1 lipid, similar to global concentrations. α-HBCD was the dominant contributor to∑HBCD
concentrations in Canadians although β- and γ-HBCDwere detected in 23% and 35% of the samples, respectively.
No differences in ∑HBCD concentration were associated with age or sex. This dataset represents the ﬁrst
national data describing HBCD isomers and some PBDEs (e.g., 183, 209) in Canadians.
Crown Copyright © 2013 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The source of greatest human exposure (N90%) to the traditional
persistent organic pollutants (POPs), including polychlorinatedreau of Chemical Safety, Health
rick Banting Driveway, Address
anada. Tel.: +1 613 941 8462;
u, Healthy Environments and
venue West, Address Locator:
r Ltd. Open access under CC BY-NC-NDbiphenyls (PCBs) and polychlorinated dibenzo-p-dioxins and diben-
zofurans (PCDD/Fs) is dietary intake (Liem et al., 2000). Flame retar-
dants such as the polybrominated diphenyl ethers (PBDEs) and
hexabromocyclododecane (HBCD) have multiple important human
exposure pathways including diet, dust ingestion and oral contact
with consumer products containing ﬂame retardants, such as toys
or textiles, while air inhalation has been suggested by some authors
(Besis and Samara, 2012; Environment Canada and Health Canada,
2011; Fraser et al., 2009; Health Canada, 2012; Meeker et al., 2009;
Roosens et al., 2009a; Shoeib et al., 2012; Sjödin et al., 2003; Trudel
et al., 2011). Occupational exposure to workers in industrial and
recycling plants also is subject to increased exposure to ﬂame retar-
dants (Eguchi et al., 2012; Sjödin et al., 1999; Stapleton et al., 2008;
Thomsen et al., 2007). Both of these classes of ﬂame retardants are
added to the product rather than chemically bonded to them and, license.
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the product's entire lifecycle including the manufacture of the end
product as well as its use and disposal (Covaci et al., 2006; Hale
et al., 2003; Shoeib et al., 2012).
With the greater usage of PBDEs in North America than in European
countries, elevated concentrations have been observed in North
American food and environmental compartments, resulting in an in-
creased exposure to people (De Wit, 2002; Domingo, 2012; Hites,
2004; Tomy et al., 2009). In contrast, HBCD usage in Europe, which
was greater than in North America, has resulted in a corresponding rel-
ative increase in concentrations observed in European environmental
and biological samples relative to North America (Covaci et al., 2006;
Johnson-Restrepo et al., 2008).
Studies using a variety of organisms to determine the effects of PBDE
and HBCD exposure at the present levels have shown that they are not
of concern in terms of acute toxicity (Darnerud, 2003). Delayed pubertal
progression has been observed in male rats exposed to PBDE formula-
tions where preputial separation delays and reduced ventral prostate
and seminal vesicle weights were reported (Korenbrot et al., 1977;
Stoker et al., 2004, 2005). Reduced sperm counts also have been re-
ported in male rats exposed to PBDE congeners (Kuriyama et al.,
2005). PBDE exposure has additionally been associated with decreased
thyroxine (T4) levels in female rats and mice even at low doses
(Ellis-Hutchings et al., 2006; Fowles et al., 1994; Kuriyama et al., 2007;
Richardson et al., 2006). PBDEs also have been associated with endo-
crine disruption and developmental neurotoxicity in humans, with pre-
natal exposure to PBDEs having resulted in decreased ﬁne motor skills
and attention (Costa et al., 2008; Eriksson et al., 1998; Legler and
Brouwer, 2003; Roze et al., 2009). Linkages have been made between
increased PBDE exposure and implications to human reproductive sys-
tems such as reduced sperm quality, increased cryptorchidism in new-
born boys and reduction in age ofmenarche in girls (Akutsu et al., 2008;
Chen et al., 2011;Main et al., 2007). No relationshipwas found between
PBDE concentrations in adipose tissue and breast cancer risk in a small
study in theUS (Hurley et al., 2011). Although less toxicological data are
available for HBCD in the literature, exposure has been linked to drug-
metabolising enzyme induction in both rats and ﬁsh (Germer et al.,
2006; Ronisz et al., 2004). HBCD exposure has resulted in decreased fer-
tility and thyroid effects in ratmodels (Ema et al., 2008). Behavioural ef-
fects also have been observed in mice (Eriksson et al., 2006). Malignant
transformation of mammalian cells also has been reported for HBCD by
some authors, although Health Canada concluded that HBCD lacks sig-
niﬁcant genotoxicity potential (Environment Canada and Health
Canada, 2011; Shaw et al., 2010).
Human biomonitoring allows direct measurement of systemic expo-
sure levels of environmental contaminants in contrast to estimates
based on the rate of uptake or route of exposure. Biomonitoring provides
a clear measurement of howmuch of a given chemical an individual has
retained in the body at the time of sample collection. Biomonitoring stud-
ies to determine human exposure to PBDEs and HBCD via targeted sur-
veys are available in the literature, however, few are representative of
entire populations and are, generally, limited to comparisons between
speciﬁc sub-groups within a population (Croes et al., 2012; Eskenazi
et al., 2011; Fraser et al., 2009; Kalantzi et al., 2011; Leijs et al., 2008;
Roosens et al., 2010; Zota et al., 2011). Prenatal exposure to brominated
ﬂame retardants has been conﬁrmed through the study of paired mater-
nal and foetal serum samples and foetal liver and placental tissue paired
sampling (Doucet et al., 2009; Mazdai et al., 2003; Schecter et al., 2007).
Additionally, analysis of humanmilk has provided ameasure of maternal
exposure to POPs and has allowed for dietary exposure estimates to in-
fants and young children through ingestion of maternal milk (Croes
et al., 2012; Inoue et al., 2006; Roosens et al., 2010). In the US, the Centers
for Disease Control and Prevention (CDC) has conducted an ongoing
study, known as the National Health and Nutrition Examination Survey
(NHANES) to determine the nutritional and health status of its popula-
tion annually (Curtin et al., 2013). As part of that national survey,serumand urine have been collected and tested tomeasure environmen-
tal contaminant concentrations (Axelrad et al., 2009; Chen et al., 2011).
The Canadian Health Measures Survey (CHMS), initially undertaken
as a one-time survey to determine national baseline estimates of the
health status of Canadians between the age of 6 and 79 years, has
evolved into an ongoing survey with different collection periods identi-
ﬁed by Cycle number (Giroux, 2007). Samples collected from adults
aged 20–79years as part of Cycle 1 of the CHMS included small volumes
of plasma (2.7 mL) for PCB and PBDE analysis (Health Canada, 2010;
Rawn et al., 2012). Sample collection for POP residue analysis in the ini-
tial CHMSCycle 1 studywas restricted to adults (i.e., individuals aged 20
to 79years) for several reasons, which included avoiding increased rate
of refusal to participate and due to the limits on the quantity of blood
which can ethically be taken from a child as part of a study. Serum
PBDE concentrationsmeasured during the Cycle 1 studywere frequent-
ly below the limit of detection in the individual samples analysed
(Health Canada, 2010). Only PBDEs 47, 99, 100 and 153 were detected
in the serum samples studied as part of the CHMS Cycle 1 with concen-
trations reported at the 50th or 75th percentile (Health Canada, 2010).
In an effort to increase the number of samples with concentrations
above the detection limits for a number of classes of POPs, including
the PBDEs andHBCD, the present studywas undertaken to prepare larger
volume pooled samples using the surplus serum from testing in Cycle 1
of the CHMS. Individual leftover serum samples from individuals ranging
in age from 6 to 79years were pooled following grouping by age and sex
to develop ~25 mL samples for analysis, using gas chromatography —
high resolution mass spectrometry and high pressure liquid chromatog-
raphy coupled to tandemmass spectrometry, to determine Canadian na-
tional baseline PBDE and HBCD concentration estimates.
2. Materials and methods
2.1. Blood collection
The CHMS Cycle 1 sampling was established to represent the
Canadian national population and included individuals living in one of
the 10 provinces or three territories, but excluded individuals living
on First Nations reserves, institutional residents and Canadian Forces
full-time members (Statistics Canada, 2010). Sampling required a min-
imum of 5000 participants over two years and distributed over ﬁve re-
gions to ensure that sampling was representative of the national
population (Statistics Canada, 2010). As described by Rawn et al.
(2012), blood ranging in volume from b28 mL to b80 mL, depending
on the age of the donor (Statistics Canada, 2010), was collected during
Cycle 1 of CHMS at mobile clinics across Canada, centrifuged, and
serum was retained in 2 mL cryogenic vials within 2 h of collection
and frozen. Serum samples were shipped weekly to the laboratory on
dry ice and stored at −20 °C until taken for pooling. The serum left
over after testing for the initially planned analyses was then re-frozen
at−20°C and stored prior to development of the pools.
2.2. Methodology for the creation of pooled serum samples
Statistics Canada developed the protocol for the creation of serum
pools from the individual samples, representative of 96.3% of the
Canadian population from age 6 to 79 years and was approved by the
Health Canada Research Ethics Board prior to initiation of the present
study (Verret and Giroux, 2010). The serum pools were formed using
sampling weights, which were calculated from a model that was used
in creating the original CHMS survey design. The sampling weights cor-
respond to howmany individuals of thepopulation thatwas being stud-
ied were represented in a given sample.
Left over serum (350 μL) from individual participants in Cycle 1 of
the CHMSwas used to create 59 serum pools with approximately 80 in-
dividuals per pool, rather than theminimumof 71 individuals needed to
obtain the desired 25mL volume of serum. Individual samples that did
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non-responders and, therefore, adjustments to the other individual
sample weights were performed (Dion and Giroux, 2011).
In order to calculate an estimate of the variance, at least two repli-
cates that represent the population of interest must be included. Be-
cause of the limited number of sample collection sites included in the
CHMS survey, there were only enough sites to create two replicate
pools. Brieﬂy, each of the two replicates contained one-half of the sites
from each of the ﬁve regions, with each replicate including all age-sex
groups. The replicates were adjusted so that an estimate from each
would reﬂect the Canadian population. The serum pools were then con-
structed with individuals from the sites assigned to that replicate, for
each age and sex combination. The pool sample weight was then calcu-
lated from the individual sampleweights. Ideally, for each serumpool to
produce a statistically valid estimate, the amount of serum used to con-
struct the pool needed to be in proportion to the sample weights of the
individuals in that pool. Because the sample volumes were low, being
leftover from previous analyses, this approach was not possible. An
alternative approach was used in this study, which was to assign indi-
viduals with similar sample weights to the same serum pool (Verret
and Giroux, 2010).
As indicated previously, each serum pool was planned using 80 par-
ticipants rather than the minimum of 71 individuals. These additional
serumsampleswere included for each pool to ensure that theminimum
acceptable sample volumes would be obtained in the pools even if
i) some participants from Cycle 1 refused to have their serum included
in this study, ii) too small a sample volume remained to contribute to
the pool development (i.e., b350 μL) and/or iii) sample loss during
handling (Verret and Giroux, 2010). Each of these situations was
encountered in at least one of the pools, but the number of samples
remaining allowed for the preparation of 59 serumpools for the present
study. The pools were distributed by sex and by ﬁve age groups
(6–11 years, 12–19 years, 20–39 years, 40–59 years, 60–79 years) and
each group was developed to reduce as much bias as possible in the es-
timates established, while allowing for the calculation of quality indica-
tors such as variance and coefﬁcients of variation (Rawn et al., 2012;
Verret and Giroux, 2010). The actual number of individuals within
each pool ranged from 57 to 120, corresponding to total serumpool vol-
umes of 20mL to 42mL (mean 27.2mL) and the study included serum
from a total of 4583 individual participants. Once prepared, the pooled
samples were stored at−80°C until needed for analyses.
2.3. Quality assurance
With each set of samples analysed, two reagent blank samples and a
low level certiﬁed reference material of serum were included in the
present study (NIST SRM 1957). An aliquot of a serum sample contain-
ing POPs at known and low concentrations, which has been repeatedly
tested in our laboratory and was known to contain measureable levels
of PBDEs and HBCD, was included with each set of samples as an inter-
nal quality control. Each sample was fortiﬁed with stable isotope ana-
logues of the analytes, as surrogate standards, prior to extraction, to
allow for recovery correction using isotope dilution.
2.4. Sample extraction and clean up
Thawed serum samples were weighed into Erlenmeyer ﬂasks and
fortiﬁed with 13C12 analogues of nine PBDE congeners and three HBCD
isomers (500pg 13C12 labelled PBDE 15, 28, 47, 99, 100, 153, 154, 183;
6250 pg 13C12 labelled PBDE 209; and 10 ng 13C12 labelled α-, β- and
γ-HBCD) (Cambridge Isotope Laboratories, Andover, MA, USA and
Wellington Laboratories, Guelph, ON, Canada). Samples were extracted
as reported previously (Rawn et al., 2012). Brieﬂy, ~25mL of both etha-
nol and water saturated with ammonium sulphate and ~75mL of hex-
ane were added to the sample and homogenised using a Polytron®,
following removal of the hexane layer, a second aliquot of hexane wasadded and the sample was re-homogenised. This was followed again
by removal of the hexane layer and both hexane aliquots were com-
bined. Raw extracts were rinsed with de-ionised water (15mL). After
the water phase was discarded, the hexane faction was dried over a
bed of pre-cleaned sodium sulphate and collected in a round bottom
ﬂask. Each sample was evaporated to dryness using rotary evaporation
and the lipid content of each sample was determined gravimetrically
and then diluted to 10mL in hexane.
Initial cleanup of extracts was performed using 2g of activated silica
gel (stored at 130 °C), pre-conditioned using 10 mL of hexane. The
PBDEs were eluted with 4mL hexane and HBCD was eluted with 6mL
1:1 hexane: dichloromethane (DCM). The PBDE fraction was further
cleaned up as described for polychlorinated dibenzo-p-dioxins/furans
previously (Rawn et al., 2012). Extracts containing PBDEs were diluted
to 100 mL in hexane, mixed gently with repeated exposure to concen-
trated sulphuric acid, rinsed sequentially with de-ionised water, 1% po-
tassium hydroxide and a ﬁnal rinse with de-ionised water. The samples
were passed through a bed of anhydrous sodium sulphate and reduced
in volume to 1 mL using rotary evaporation. Further cleanup of the
PBDE fraction was performed using two columns in vertical series with
one containing 2g acidiﬁed silica gel and the other 1.5g of 100% activated
Florisil and eluted initially with 40 mL hexane. This fraction contained
PBDE 209. The Florisil was eluted with a further 60 mL DCM to isolate
the remaining PBDEs and this fraction was then evaporated to 1 mL
under vacuum. A ﬁnal clean up step for the PBDE fractionwas performed
using a 0.4 g 18% Carbopack C: Celite column where the analytes were
elutedwith 2mLhexane, 1mL (1:1) hexane: DCM, evaporated to dryness
and reconstituted with 10μL of a 50pgμL−1 solution containing the per-
formance standards PCB 200, 209 and decachlorodiphenyl ether in tolu-
ene and placed into v-vials for gas chromatographic-high resolution
mass spectrometric analysis. The fraction containing PBDE 209 was con-
centrated to dryness and reconstituted in 10μL of a 250pgμL−1 solution
of decabromobiphenyl.
The HBCD fraction of each sample was evaporated to near dryness,
diluted to 1mL in hexane and cleaned up using acidiﬁed silica gel and
eluted using 20 mL hexane, concentrated just to dryness passively
followed by a gentle stream of nitrogen and reconstituted with 20 μL
of a solution containing 250pgμL−1 deuterated C122 H18Br6 HBCD perfor-
mance standard in methanol:water (80:20) followed by the addition of
80 μL 80:20 methanol:water, prior to analysis (Rawn et al., 2011).
2.5. Analysis
Fifty-nine pools of sera were analysed for 23 polybrominated
diphenyl ethers using high resolution gas chromatography–isotope-di-
lution high-resolution mass spectrometry (HRGC/ID-HRMS), while 57
pooled serum samples were analysed to determine HBCD concentra-
tions (two samples were lost during sample preparation).
PBDE analyses were performed using a Micromass AutoSpec Ultima
high resolution mass spectrometer (Waters Corporation, Milford,
Massachusetts, USA) coupled to an Agilent 6890 gas chromatograph
(Mississauga, ON). A 15 m J&W DB5 MS (0.25 mm i.d. × 0.10 μm ﬁlm
thickness) columnwas used for separation of the analytes following in-
troduction of a 1 μL sample volume into the cool on-column injection
systemwhichwas set to track the oven temperature. The initial temper-
ature was set to 80°C and held for 1min, increased to 225°C at a rate of
32°Cmin−1 andheld at 225°C for 1min followed by an increase at a rate
of 3°Cmin−1 to 230°C and held for 8min. The ﬁnal increase was set at a
rate of 40°Cmin−1 to 295°C. The head pressure initially was 28kPa and
held for 2min, followed by an increase at a rate of 7kPamin−1 to 83kPa
and held for 15 min with a ﬁnal increase to 173 kPa at a rate of
69kPamin−1. Helium was used as the carrier gas for all PBDE analyses
and the mass spectrometer was operating in EI positive ion mode at
36 eV, the trap current was 600 μA and the source temperature was
250 °C. The tuning and resolution for all analytes were approximately
10000 (10% valley deﬁnition).
Table 1
Summary statistics of the population level estimates ofmajor congeners and∑PBDEa and
HBCD (α-, β-, γ- and ∑) concentrations (ng g−1 lipid) in Canadian serum samples
determined following weighting of pooled samples; values bLOD have been replaced
with LOD/√2.
Compound Min Max Mean Coefﬁcient of variation b(%) Geometric mean
PBDE 47 12 43 23 5.7 22
PBDE 99 1.9 61 5.4 4.1 4.6
PBDE 100 2.0 11 4.4 7.8 4.1
PBDE 153 4.7 21 10 10 9.4
PBDE 183 0.27 2.4 0.46 1.1 0.42
PBDE 209 0.02 9.6 1.9 2.5 1.1
ΣPBDEsa 27 130 48 5.5 46
α-HBCD 0.13 6.3 0.63 30 0.4
β-HBCD 0.04 1.1 0.14 5.0 0.12
γ-HBCD b0.01 1.6 0.11 27 0.06
∑HBCDc 0.33 8.9 1.0 23 0.85
a ∑ of PBDE 15, 17, 28, 37, 47, 66, 71, 75, 77, 85, 99, 100, 119, 126, 138, 153, 154, 160,
181, 183, 190, 205, and 209.
b Coefﬁcient of variation (CV): 0.0≤ CV≤ 16.6 acceptable; 16.6≤ CV≤ 33.3 use with
caution.
c ∑ of α-, β- and γ-HBCD.
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Mississauga, ON, Canada) high pressure liquid chromatograph coupled
to a Quattro Ultima triple quadrupole MS/MS (Waters Corporation,
Milford, Massachusetts, USA) with electrospray ionisation in the
negative ion detection mode using a Phenomenex Kinetex C18
(2.1mm×150mm, 2.6μm column) (Phenomenex, Torrance, CA, USA).
Water (mobile phase A) and acetonitrile:methanol (2:1 v/v) (mobile
phase B) were used in separation of the HBCD isomers and the gradient
was as follows: 40% mobile phase B for 1min, 40 to 80% mobile phase B
by 4min, 80 to 90% B by 13min, and then returned to 40% B over 0.5min
where it remained until 18 min. The ﬂow rate was maintained at
0.22 mLmin−1 and the column temperature was maintained at 30 °C
to completely resolve the deuterated HBCD analogues from the
13C-labelled and native analogues. The capillary and cone voltage were
−3.0kV and 35V, respectively. The source temperature and desolvation
temperature were 140 °C and 350 °C, respectively. Cone gas ﬂow and
desolvation gas ﬂow were 77 L h−1 and 723 L h−1, respectively. Argon
was the collision gas set at 5×10−3mbar and resolutionwas established
at 90% valley at base for both quadrupole analyzers. Dwell times were
set to 5ms (Rawn et al., 2011).
2.6. Data reporting and statistical analysis
∑PBDE concentrations are reported as a sum of 23 congeners (15,
17, 28, 37, 47, 66, 71, 75, 77, 85, 99, 100, 119, 126, 138, 153, 154, 160,
181, 183, 190, 205, 209) and∑HBCD concentrations are the sum of
α-, β- and γ-HBCD on a lipid extractable basis with the lipid content
determined gravimetrically. Values below the detection limit were
substituted with LOD/√2 for reporting purposes, which has been
shown to result in more accurate estimates of the mean concentration
when some results are below the limit of detection (Baccarelli et al.,
2005; Hornung and Reed, 1990).
Following the methodology for statistical analyses, using SAS 9.2, as
outlined in Dion and Giroux (2011) pooled surveyweights were associ-
ated with each pool. Population estimates of means and geometric
means by age and sex were calculated from these weighted pools
(Dion and Giroux, 2011). The quality indicators of the estimates of the
means, variance and coefﬁcient of variation were similarly determined
(Dion and Giroux, 2011).
Due to the assumptions of normality and equal variance not being
met for PBDEs and HBCD, and the strategy of using only two replicates
in the construction of the serum pools, the variance estimator was con-
sidered unstable, hence all the data were rank transformed.
Relationships between the congeners contributing signiﬁcantly to
∑PBDE concentrations were evaluated using Spearman correlations
using SigmaStat. To guard against spurious results and to maintain, as
close as possible, an overall error rate of 5% for the testing of the corre-
lation coefﬁcients, the Bonferroni approach was used in testing the
pairwise correlations. Therefore, testing of each correlation is at an
error rate of 5% divided by the number of tests (21); thus the testing
for signiﬁcance for each pair of correlations is at 0.2% and not 5% level.
3. Results
3.1. Quality assurance
Average surrogate standard recovery of the PBDEs ranged from 23%
to 56%, PBDE 15 and 100, respectively. Because the method was origi-
nally optimised for the determination of PCBs and PCDD/Fs, themethod
applied resulted in lower than ideal PBDE recoveries. The average
recoveries for 13C HBCD analogue recoveries ranged from 86% (β- and
γ-HBCD) to 91% (α-HBCD). All reported sample concentrations were
corrected for recoveries using isotope dilution. Laboratory background
was accounted for by removing the average of the PBDE and HBCD con-
centrations observed in the two reagent blank samples for each set of
samples analysed.The results of the internal quality assurance samplewerewithin two
standard deviations of the mean concentration observed over the time
this sample has been analysed. The PBDE concentrations observed in
the certiﬁed referencematerial testedwere in agreementwith expected
reference concentrations, with average concentrations found to be
within two standard deviations of the certiﬁed value. The exceptions
were PBDEs 66 and 85,whichwere frequently observed to be at concen-
trations below certiﬁed values. Although HBCD is not certiﬁed in the
reference material tested, low concentrations of α-HBCD with β- and
γ-HBCD near the limit of detection were observed.
The average PBDE limits of detection (LOD) were determined based
on a 3:1 signal to baseline noise ratio for each set of samples analysed,
and ranged from 0.058 pg g−1 to 1.47 pg g−1 whole weight in the
serum sample pools analysed. HBCD limits of detection were deter-
mined as an average response for the four transitionsmeasured. The ab-
solute instrumental detection limits were determined based on 15 μL
injection volumes and established as averages for each set of samples
using a 3:1 signal to baseline noise ratio. The average LOD ranged
from 1.00pgg−1 (γ-HBCD) to 1.87pgg−1 (β-HBCD), while the average
LOD for α-HBCD was 1.10pgg−1 whole weight. Lipid content based on
gravimetric determination, in individual samples, ranged from 0.48% to
0.76% with a mean of 0.61% lipid.
Replacing values below the detection limit with LOD/√2 for
reporting purposes allowed for comparability with results of the Na-
tional Health and Nutrition Examination Survey (NHANES). Population
estimates of means and geometric means were derived using the con-
centration data obtained from the residue analysis and took into ac-
count survey weights (Tables 1, 2 & 3), however, the graphical
representation of the data corresponds to concentrations as observed
in the unweighted serum pools (Figs. 2, 3 & 4) (Dion and Giroux, 2011).3.2. Concentrations and trends in serum pools
PBDEs were detected in all samples analysed (n=59) in the present
study with ∑PBDE concentrations ranging from 27 ng g−1 lipid to
130 ng g−1 lipid (Table 1, 2) and the geometric mean [GM] ∑PBDE
concentration of 46ngg−1 lipid (Table 1). Consistentwith the extensive
use of the penta-PBDE mixture in North America, the tetra- and
pentabrominated congeners provided the major contributions to PBDE
concentrations in the Canadian serum samples tested as part of this
study. PBDE 47 was the predominant PBDE congener, followed by
PBDE 153N 99 N 100N 209 and 183 with average contributions ranging
Table 2
Population estimates (weighted) of major congeners and ∑PBDEa concentrations in
Canadian serum samples (ng g−1 lipid) by age group; values bLOD have been replaced
with LOD/√2.
Congener Age
(y)
Number
of pools
Min Max Mean Coefﬁcient of
variationb (%)
Geometric
mean
47 6–11 10 20 43 32 11 30
12–19 10 21 38 26 8.7 25
20–39 13 16 27 22 16 21
40–59 14 12 41 25 1.4 23
60–79 12 17 34 24 3.1 23
99 6–11 10 4.4 11 7.6 11 7.3
12–19 10 3.8 9.0 5.5 9.8 5.3
20–39 13 2.7 61 5.9 16 4.4
40–59 14 2.9 11 5.0 6.0 4.6
60–79 12 1.9 9.2 4.0 2.4 3.5
100 6–11 10 4.2 8.0 6.2 6.7 6.1
12–19 10 3.2 5.3 4.0 6.0 4.0
20–39 13 2.9 11 4.7 15 4.5
40–59 14 2.0 8.4 4.0 3.8 3.8
60–79 12 2.3 8.0 3.9 14 3.6
153 6–11 10 10 20 14 4.0 13
12–19 10 5.3 12 7.8 1.4 7.5
20–39 13 6.3 20 12 13 11
40–59 14 5.6 17 9.2 10 8.7
60–79 12 4.7 21 8.5 24 8.0
183 6–11 10 0.28 0.52 0.39 8.6 0.39
12–19 10 0.27 2.1 0.67 43 0.50
20–39 13 0.27 2.4 0.39 7.3 0.36
40–59 14 0.34 0.73 0.47 11 0.46
60–79 12 0.28 0.76 0.45 5.3 0.44
209 6–11 10 2.5 9.6 4.3 30 3.8
12–19 10 0.02 4.1 1.3 2.3 0.46
20–39 13 0.03 7.2 1.9 25 1.4
40–59 14 0.03 2.9 1.5 2.5 0.72
60–79 12 0.02 4.3 2.0 5.4 1.4
ΣPBDEsa 6–11 10 43 87 67 11 65
12–19 10 34 70 47 5.9 46
20–39 13 28 130 50 11 47
40–59 14 27 83 46 4.3 44
60–79 12 27 77 43 8.1 41
a ∑ of PBDE 15, 17, 28, 37, 47, 66, 71, 75, 77, 85, 99, 100, 119, 126, 138, 153, 154, 160,
181, 183, 190, 205, and 209.
b Coefﬁcient of variation (CV): 0.0≤ CV≤ 16.6 acceptable; 16.6≤ CV≤ 33.3 use with
caution; CVN33.3. The user is advised that the data do notmeet Statistics Canada's quality
standards for this statistical programme and conclusions based on these data will be unre-
liable and most likely be invalid.
Table 3
Population estimates (weighted) of∑HBCDa concentrations in Canadian serum samples
(ng g−1 lipid) by age group; values bLOD have been replaced with LOD/√2.
Isomer Age
(y)
Min Max Mean Coefﬁcient of
variationb (%)
Geometric
mean
α-HBCD 6–11 0.17 6.3 0.85 47 0.45
12–19 0.13 1.6 0.62 38 0.43
20–39 0.16 1.0 0.42 14 0.38
40–59 0.24 0.91 0.53 22 0.49
60–79 0.28 3.4 1.1 55 0.73
β-HBCD 6–11 0.08 1.1 0.21 37 0.15
12–19 0.08 0.58 0.23 22 0.19
20–39 0.04 0.22 0.15 13 0.14
40–59 0.06 0.21 0.11 0.54 0.10
60–79 0.07 0.14 0.10 14 0.10
γ-HBCD 6–11 0.04 1.5 0.20 42 0.11
12–19 0.01 1.6 0.31 80 0.08
20–39 b0.01 0.21 0.09 17 0.07
40–59 0.02 0.06 0.05 10 0.05
60–79 b0.01 0.11 0.06 0.06 0.05
∑HBCDa 6–11 0.51 8.9 1.4 39 0.89
12–19 0.50 3.3 1.3 41 0.99
20–39 0.33 1.2 0.78 7.7 0.75
40–59 0.43 1.1 0.82 13 0.79
60–79 0.51 3.8 1.5 47 1.1
a ∑ of α-, β- and γ-HBCD.
b Coefﬁcient of variation (CV): 0.0≤ CV≤ 16.6 acceptable; 16.6≤ CV≤ 33.3 use with
caution; CVN33.3. The user is advised that the data do notmeet Statistics Canada's quality
standards for this statistical programme and conclusions based on these data will be
unreliable and most likely be invalid.
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Fig. 1. Contribution of individual PBDE congener to∑PBDE concentrations by age and sex
(M=male; F= female).
30 D.F.K. Rawn et al. / Environment International 63 (2014) 26–34from 48% to 1% (Fig. 1). These results are consistent with observations
obtained during the analysis of the individual serum samples as part
of Cycle 1 of the CHMS, where only PBDE 47, 99, 100 and 153 were
detected in low volume samples (Health Canada, 2010). PBDE 47 con-
centrations were between 12 ng g−1 lipid and 43 ng g−1 lipid ([GM]
22 ng g−1 lipid) in the present study. PBDEs 47, 99, 100 and 153 were
observed in 100% of the pooled serum samples. PBDE 209 contributed
an average of 4% to ∑PBDE concentrations, though it was only ob-
served in 88% of the samples while PBDE 183 was observed in all 59
samples analysed but contributed only an average of 1% to ∑PBDE
concentrations.
Differences in ∑PBDE concentrations were observed among the
ﬁve age groups tested. Pools containing serum from individuals aged
6–11 years had higher∑PBDE concentrations than those obtained in
serum pools comprising individuals 40–59 years old and 60–79 years
old. This difference may be associated with dietary and behavioural ac-
tivity patterns in young children (e.g., playing with toys on the ﬂoor,
where they are exposed to household dust). Overall, a slight decrease
in PBDE concentration across the age groups was observed, with the
youngest age group tested (6–11years) havingmaximum∑PBDE con-
centrations (GM=65ngg−1 lipid) and lowest concentrations found in
samples from the older age groups (GM= 44 ng g−1 lipid, 41 ng g−1
lipid; 40–59 and 60–79 years, respectively) (Table 2, Fig. 2). This trend
contrasts with the TEQPCDD/F + Dioxin-Like-PCB concentration patternobserved in these same samples, which increased with age (Rawn
et al., 2012).
∑HBCD concentrations (0.33–8.9ngg−1 lipid) were detected in all
samples analysed (n=57), but concentrations were much lower than
∑PBDE concentrations in the pooled serum samples (27–130 ng g−1
lipid; Tables 1, 3).∑HBCD concentrations were below 1 ng g−1 lipid
in 88% of the samples analysed (Fig. 3). Given the low concentrations ob-
served in the present study, a larger coefﬁcient of variationwas obtained,
which results in lower conﬁdence in the population level estimates de-
termined (Tables 1, 3). The maximum concentration observed was in a
pool of serum comprising males aged 6–11 years (Fig. 3). Although
most of the samples with higher∑HBCD concentrations were observed
in pools of male serum, the maximum concentration observed in the
60–79year age group comprised a female pool (3.8ngg−1 lipid) (Fig. 3).
Consistently, theα-HBCDwas the dominant contributor to∑HBCD
concentrations in the samples tested (Table 3). α-HBCD was observed
in all of the samples analysed, β-HBCD was detected in 13 samples
20
40
60
80
100
120
140
Male
Female
6 – 11 12 – 19 20 – 39 40 – 59 60 – 79
∑P
BD
E 
Co
nc
en
tra
tio
n 
(ng
 g-
1  
lip
id
)
Age (years)
Fig. 2.∑PBDE concentrations in Canadian human serumpools distributed by age (years).
31D.F.K. Rawn et al. / Environment International 63 (2014) 26–34(23%) andγ-HBCD in 20 samples (35%).Mean contributions to∑HBCD
were 87%, 6% and 7% in the serumpools analysed forα-, β- andγ-HBCD,
respectively; for this result the serum pool weights were not used.
4. Discussion
The PBDE congener proﬁle observed in the present study agreeswell
with results obtained from North America previously. As expected, due
to the averaging effect of pooling,maximumconcentrations observed in
the present study (130ngg−1 lipid) are lower than consistently report-
ed in the US and Canada (e.g., 637 ng g−1 lipid, 1010 ng g−1 lipid,
1100 ng g−1 lipid, 1290 ng g−1 lipid, 1360 ng g−1 lipid, 1590 ng g−1
lipid) (Anderson et al., 2008; Castorina et al., 2011; Chen et al., 2011;
Eskenazi et al., 2011; Fitzgerald et al., 2010; Foster et al., 2011). The con-
geners contributing the greatest to North American∑PBDE body bur-
dens include 47, 153, 99 and 100, similar to the pentaBDE commercial
product which was used extensively in North America, with relatively
lower concentrations of those congeners present in the OctaBDE mix
(DeWit, 2002; Johnson et al., 2010;Mazdai et al., 2003). Serum concen-
trations of PBDE 47 from the US NHANES study (2003–2004) were the
highest of all congeners detected in every group examined in the
study with GM concentrations of 20.5ngg−1 lipid (Sjödin et al., 2008),
which is similar to what was observed in the present study (GM =
22ngg−1 lipid).
A single pooled serum sample was observed to have higher∑PBDE
concentrations than the others, with individual congeners skewing the0
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Fig. 3.∑HBCDconcentrations inCanadianhuman serumpools distributed by age (years).results when correlations between congeners were investigated. As a re-
sult of these implications, this sample was not included in an assessment
of the correlation between the congeners that contributed most to the
∑PBDE concentrations. Signiﬁcant Spearman correlations (p b 0.002)
were established between PBDE 47 and the dominant pentabrominated
congeners (99, 100) in addition to the hexabrominated PBDE 154
(Fig. 4A, B, D). A correlation between tetra- and pentabrominated conge-
ners is consistent with the pentaBDE technical products which are
known to be usedwidely inNorthAmerica (DeWit, 2002). Aweaker cor-
relationwas observed between PBDE 153 and PBDE 47 (Fig. 4C), howev-
er, PBDE 153 concentrations in Canadian serumwere correlatedwith the
pentabrominated PBDE 99 and 100 (p b 0.002), similar to PBDE 154
(pb0.002). The hexabrominated PBDE 153 and 154 congeners were sig-
niﬁcantly correlated with each other (p b 0.002), however, no correla-
tions were associated with PBDE 183 or PBDE 209 and the other
dominant congeners. The observation of signiﬁcant correlations between
the hexa-substitutedwith the penta-substituted congeners is also consis-
tent with the presence of these congener classes in the OctaPBDE
technical product. DecaBDE technical products in North America
did not contain appreciable amounts of the lower brominated conge-
ners (De Wit, 2002), consistent with the lack of correlation between
it and the other major congeners present in the serum of Canadians
(47, 153, 99, 100, 183). The Canadian serum results observed in the
present study reﬂect the use of PBDE technical products consistent
with known product demand and use (De Wit, 2002).
Many of the publications from the early 2000s reporting serumPBDE
concentrations did not include PBDE 209 among their analytes and thus,
overall PBDE concentrationsmay have been under reported to some de-
gree in earlier studies. Despite different researchers including a different
number of congeners for∑PBDE determinations (e.g.,∑4,∑5,∑7),
the dominant contributors to∑PBDEs in human serum tend to be lim-
ited to a select few and capture themajor congeners of interest (e.g., 47,
99, 100, 153, 183, 209) (Table 1) (Castorina et al., 2011; Kalantzi et al.,
2011; Thomsen et al., 2008). In the present work, PBDE 209 contributed
approximately 4% to∑PBDE concentrations regardless of age group or
sex considered (Fig. 1; Table 1).
The predominant contributor to∑PBDEs in serum collected in two
regions of Madrid, Spain was PBDE 47 (0.26–22ngg−1 lipid), followed
closely by 99 (1.1–12ngg−1 lipid) and 100 (0.77–4.2ngg−1 lipid), indi-
cating that the congener pattern was similar to observations in the
Canadian serum pools (Gómara et al., 2007). The Canadian geometric
mean PBDE 47 concentration (22 ng g−1 lipid; Table 1), however, was
approximately an order of magnitude greater than mid-range concen-
trations reported in Spain (median ~ 2.5 ng g−1 lipid), while the
pentabrominated congeners (e.g., 99 and 100) in Canadian samples
(Table 1)were only approximately a factor of two greater thanobserved
in Spain (Gómara et al., 2007).
Serum pool samples collected in Australia between 2002 and 2009
also found PBDE 47 to be the dominant congener while PBDE 209
contributed b6% to∑PBDE concentrations, similar to the Canadian ob-
servations (Toms et al., 2008). Additionally younger Australians
(b16 years) were shown to have higher∑PBDE concentrations than
adults (73±7ngg−1 lipid; b16year olds, vs. 29±7ngg−1 lipid; adults),
which is consistentwith the pattern observed in this study (Table 2), al-
though Australian serum concentrations exceeded the Canadian serum
concentrations observed in the 6–11 year age group despite measure-
ments being performed in serum pools in both studies (Toms et al.,
2008). PBDE 47was similarly the dominant contributor to∑PBDE con-
centrations (1.04 ng g−1 lipid) in a single pooled serum sample from
eastern Romania, followed by 99, 100, 183 and 153, which indicates a
similar congener proﬁle to patterns observed in North American, albeit
at much lower concentrations than observed in Canada (Dirtu et al.,
2006). Although similar congener patterns were observed in Spain rel-
ative to North America, they contrast with results from Belgium, the
Netherlands and the U.K. which found that PBDE 153 dominated
serum ∑PBDE concentrations (Meijer et al., 2008; Roosens et al.,
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32 D.F.K. Rawn et al. / Environment International 63 (2014) 26–342009a, 2010; Thomas et al., 2006). PBDE 209 only occurred in 13% of in-
dividual human serum collected in Greece, when it was present PBDE
209 (1.18–19.1ngg−1 lipid) contributed greatly to∑PBDE concentra-
tions (Kalantzi et al., 2011).
Asian countries have found that PBDE 209 and other higher bromi-
nated PBDE congeners contribute the greatest to serum∑PBDE con-
centrations (Eguchi et al., 2012; Inoue et al., 2006; Jin et al., 2009;
Wang et al., 2012). The contribution to∑PBDE from the tri- through
heptabrominated congenerswas b10% in Chinawhere∑PBDE concen-
trations ranged from 0.48 ng g−1 lipid to 1980 ng g−1 lipid (mean
46.3 ng g−1 lipid) in serum from three groups of individuals (ofﬁce
cleaners, university students and police) known to not be involved in
electronic waste activities (Zhu et al., 2009). The decabromodiphenyl
ether (PBDE 209) contributed nearly 80% (36.4 ng g−1 lipid) to the
total mean∑PBDE concentration (46.3ngg−1 lipid) (Zhu et al., 2009).
By pooling the serum in the present study for analysis, the results
were expected to accurately reﬂect the measure of central tendency of
the ﬂame retardant concentrations in individual samples, but it was
recognised that these composite or pooled samples were not expected
to accurately reﬂect the full range of extreme values (Rawn et al., 2006).
The data collected in the present study have allowed for comparisons be-
tweenmid-level concentrations (mean, geometricmean ormedian, as re-
ported in the literature) from different countries including the US and
Europe. Although maximum concentrations are lower than observed in
studies where serum from individuals has been tested, this is to be ex-
pected when pooling serum to achieve a sufﬁcient volume for analyses,
owing to the dilution factor from samples containing low concentrations.
Maximum PBDE concentrations observed in individual maternal serum
samples from Ontario, Canada were 1290ngg−1 lipid, far exceeding the
results obtained in the present study (130ngg−1 lipid); however, central
concentrations were relatively similar between the two studies (GMma-
ternal 60.4ng g−1 lipid; present study GM 46ngg−1 lipid) (Foster et al.,2011). Heavy ﬁsh consumers living in regions near electric capacitor fa-
cilities also were found to have maximum ∑PBDE concentrations
(1590 ng g−1 lipid) far in excess of the results obtained in the present
study, although median concentrations (23.9 ng g−1 lipid) were lower
than the GM∑PBDE concentration (46 ng g−1 lipid) found in this Ca-
nadian study (Fitzgerald et al., 2010). The concentrations measured in
the present study were generally below the∑PBDE concentrations re-
ported in a serum pool (61.8 ng−1 lipid) and a whole blood pool
(79.7ngg−1 lipid) from the US in 2003, although the median concentra-
tion obtained from individual whole blood samples from the same year
was lower (29.6 ng g−1 lipid) than observed in the present study
(Schecter et al., 2005). The NHANES studies, which included measure-
ment of PBDEs in individual serum samples, resulted in much higher
maximum concentrations despite comparable measurement of central
values (Anderson et al., 2008; Chen et al., 2011; Sjödin et al., 2008).
More recent PBDE concentration measurements from the US population
have been performed using pooled samples with mean PBDE 47 con-
centrations ranging from 20.5 ng g−1 lipid in the 40–59 year age
group sampled between 2007/08 and 74.9 ng g−1 lipid in a pool
from the 12–19 year age group sampled in 2005/06 (U.S. Department
of Health and Human Services Centers for Disease Control and
Prevention, 2013). The proportion of PBDE 209 concentrations below
the detection limits was too high to provide a valid result (2005/06,
2007/08) (U.S. Department of Health and Human Services Centers for
Disease Control and Prevention, 2013).
Limited data in human sera exist with which to compare∑HBCD
concentrations and patterns determined in the present study, although
HBCD has been reported in a few human samples worldwide. Literature
results generally agree with observations made in the present work
(Table 3), where HBCD concentrations were below 1 ng g−1 lipid
(GM=0.85 ng g−1 lipid) despite a 100% occurrence. Median∑HBCD
concentrations in serum samples collected in the Netherlands in 2003/
33D.F.K. Rawn et al. / Environment International 63 (2014) 26–342004 were reported to range from 0.20 ng g−1 lipid to 1.1 ng g−1 lipid
(median 0.32 ng g−1 lipid) (Covaci et al., 2006). A much higher maxi-
mum∑HBCD concentration (0.49–38.8 ngg−1 lipid) was observed in
Greek serum samples than determined in the present study (8.9ngg−1
lipid), although median concentrations were only approximately twice
those obtained in Canada (Kalantzi et al., 2011). The concentration
range (below detection — 7.4ngg−1 lipid) observed in maternal serum
from women in the Netherlands during 2001–2002 was very similar to
the range observed in Canadian serum samples (0.33–8.9 ng g−1 lipid)
and to the∑HBCD concentrations reported in Belgian university stu-
dents during 2007 (below detection — 11 ng g−1 lipid) (Meijer et al.,
2008; Roosens et al., 2009b). Scandinavian workers occupationally ex-
posed to∑HBCDwere found to havemean andmedian serum concen-
trations of ∑HBCD in excess of 100 ng g−1 lipid, while non-
occupationally exposed individuals had concentrations similar to those
obtained in this Canadian study (b1 ng g−1 lipid) (Thomsen et al.,
2007). Serum∑HBCD concentrations in women either married or pre-
viously married to ﬁshermen in Sweden ranged from below the limit of
detection to a maximum concentration of 3.4ngg−1 lipid, similar to the
present study (Weiss et al., 2006). Although the technical product is
dominated by γ-HBCD, human samples have been found to contain pri-
marily α-HBCD, and β-HBCD is reported infrequently or not observed
(Johnson-Restrepo et al., 2008; Thomsen et al., 2007; Weiss et al.,
2006). In the present study, β-HBCD was detected in less than 25% of
the samples. The α-isomer was the dominant contributor to∑HBCD
concentrations, similar to observations elsewhere. Unlike∑PBDEs,
serum ∑HBCD concentrations seem to be comparable around the
globe, althoughmuch higher concentrations are observed in individ-
uals involved in polystyrene production.
Themean concentrations determined in this studywill serve as initial
Canadian national baseline estimate for HBCD and several PBDEs, and
theywill allow for trend development following completion of riskman-
agement activities into the future. Although the population estimate is
acceptable, the estimate of the variance is based on two points leading
to the possibility that the variance estimator is unstable (Verret and
Giroux, 2010). The NHANES data which report national PBDE concentra-
tions in serum from the US population as represented by ethnic back-
ground, have been determined in individual samples or as pooled
samples from 2003/04, however, at this time, a consistent temporal
trend in concentrations is not readily apparent (U.S. Department of
Health and Human Services Centers for Disease Control and Prevention,
2013). Additionally, although the pooling of serum to develop larger
sample volumes resulted in detectable concentrations of the ﬂame retar-
dants under investigation in the present study, the results more closely
represent central concentration estimates, rather than indications of
the extreme concentrations possible in individuals.Acknowledgments
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